PharmaCielo has made an initial shipment of CBD Isolate to a Canadian life sciences company that specializes in developing and commercializing proprietary drug-delivery technologies (the “Customer”). The Customer intends to use PharmaCielo’s Active Pharmaceutical Ingredients (APIs) for expanded research and development of their innovative, proprietary sublingual product platform.
“We are very pleased to have partnered with this well-established Canadian life sciences player to take an active role in the development of its next-generation innovative drug delivery system,” said Henning von Koss, CEO of PharmaCielo. “A key part of our global B2B strategy is to partner with the right product developers in key markets and get into the supply chain early, based on our high-quality formulations and ability to provide consistency at scale. While it can take time for a new product to make it to market, by partnering at the development stage, we are following a well-established playbook from more advanced industries such as the pharma, flavor, and fragrance markets. We believe that early involvement positions PharmaCielo’s products as an integral part of the value chain, with the potential for long-term margins commensurate with that position.”
Mr. von Koss continued, “We are actively building out our sales organization and our current Canadian-based business development professional is in ongoing discussions with several potential customers in both the U.S. and Canada. As more traditional players such as pharmaceutical and CPG companies continue to come to market, we expect to see a growing demand for a high-quality product and formulation expertise in the B2B channel, which will benefit PharmaCielo.”